Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

67.71 -0.15 (-0.22%)
Streaming Delayed Price Updated: 12:51 PM EDT, May 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Gilead Sciences

< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
Four Questions With Sade Clacken Joseph: Using Film As a Change Agent
SOURCE: Gilead Sciences 
Via 3BL Media
Topics Religion
Exposures Religion
Gilead and Merck Initiate Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Lenacapavir and Investigational Islatravir for HIV-1 Treatment in Virologically Suppressed Adults
From Gilead Sciences, Inc.
Via Business Wire
Global Parkinsons Disease Drugs Market Market Development Overview 2021:Johnson & Johnson, Gilead Sciences, Pacira
QY Research has made a brilliant attempt to elaborately and meticulously analyze the global Parkinsons Disease Drugs market in its latest report. All of the market forecasts presented in the report are... 
Via SBWire
Topics Initial Public Offering
Exposures Securities Market
Gilead Presents Long-Term Switch Data Reinforcing Biktarvy® as a Treatment Option for a Broad Range of People Living With HIV
From Gilead Sciences, Inc.
Via Business Wire
Gene Therapy Market Worth $13.0 Billion by 2024 - Exclusive Report by MarketsandMarkets(TM)
Chicago, Illinois--(Newsfile Corp. - October 20, 2021) - According to the new market research report "Gene Therapy Market by Vectors... 
Via Newsfile
Putting Faith Into Conversations About HIV in the Southern United States
SOURCE: Gilead Sciences 
Via 3BL Media
Gilead Sciences Announces Veklury® Donations to Help Address the Ongoing COVID-19 Crisis in Indonesia and Armenia
From Gilead Sciences, Inc.
Via Business Wire
U.S. Food and Drug Administration Approves Expanded Indication of Gilead’s Biktarvy® for Treatment of HIV-1 in Pediatric Populations
From Gilead Sciences, Inc.
Via Business Wire
Sacituzumab Govitecan Receives Positive CHMP Opinion as 2L Treatment for Adult Patients With Metastatic Triple-Negative Breast Cancer
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences to Release Third Quarter 2021 Financial Results on Thursday, October 28, 2021
From Gilead Sciences, Inc.
Via Business Wire
Interns Help Facilitate Breast Cancer Conversations Among Young Black Women
SOURCE: Gilead Sciences 
Via 3BL Media
Gilead Launches Pharmaceutical Education Program to Increase Workplace Diversity
SOURCE: Gilead Sciences 
Via 3BL Media
U.S. FDA Approves Kite’s Tecartus® as the First and Only Car T for Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
From Gilead Sciences, Inc.
Via Business Wire
Kite Submits Supplemental Biologics License Application to U.S. Food and Drug Administration for Earlier Use of Yescarta® in Large B-cell Lymphoma
From Kite
Via Business Wire
Gilead Marks Fifth Approval for Trodelvy® in Metastatic Triple-Negative Breast Cancer Under Project Orbis Initiative with Health Canada Authorization
From Gilead Sciences, Inc.
Via Business Wire
Veklury® (Remdesivir) Significantly Reduced Risk of Hospitalization in High-Risk Patients with COVID-19
From Gilead Sciences, Inc.
Via Business Wire
Longwood Fund Announces Longwood Healthcare Leaders, a Virtual Meeting for Industry Leaders on Oct. 4-5, 2021
Longwood Fund, an early-stage life science venture firm focused on company creation, will convene several hundred top biotech and pharmaceutical leaders at its fall Longwood Healthcare Leaders meeting,... 
Via Newswire.com
Four Questions With Tracey Iraca: Combating Age-Related Disparities in Blood Cancer Treatment
SOURCE: Gilead Sciences 
Via 3BL Media
Gilead to Present Latest Antiviral Research Data Addressing Urgent Global Needs in Infectious Disease at IDWeek 2021
From Gilead Sciences, Inc.
Via Business Wire
New Data Demonstrate Trodelvy® Survival Benefit in Metastatic Triple-Negative Breast Cancer Patients Regardless of Initial HR/HER2 Status
From Gilead Sciences, Inc.
Via Business Wire
Trodelvy® Significantly Improved Quality of Life Over Standard of Care in 2L+ Metastatic Triple-Negative Breast Cancer in Phase 3 ASCENT Study
From Gilead Sciences, Inc.
Via Business Wire
Wake Forest University School of Divinity Brings Faith to the Gilead COMPASS Initiative®
SOURCE: Gilead Sciences 
Via 3BL Media
Topics Religion
Exposures Religion
Gilead to Present New Data at ESMO Congress 2021 Reinforcing the Practice-changing Potential of Trodelvy
From Gilead Sciences, Inc.
Via Business Wire
Kay Yow Cancer Fund Works to Bolster Research, Increase Access to Care
SOURCE: Gilead Sciences 
Via 3BL Media
Topics Death
Exposures Death
Gilead Sciences to Present at Upcoming Investor Conference
From Gilead Sciences, Inc.
Via Business Wire
Human Rights Campaign and Gilead Will Work Together to Combat HIV Epidemic and Promote Transgender Justice
SOURCE: Gilead Sciences 
Via 3BL Media
European Medicines Agency Validates Gilead’s Marketing Authorization Application for Lenacapavir, an Investigational, Long-Acting Capsid Inhibitor for the Treatment of HIV-1 in People With Limited Therapy Options
From Gilead Sciences, Inc.
Via Business Wire
China's Red Ribbon School Provides a Refuge for Children Living With HIV
SOURCE: Gilead Sciences 
Via 3BL Media
Topics Bonds Product Recall
Exposures Debt Markets Legal Product Safety
Gilead Sciences Endows Its Foundation With More Than $200 Million to Support Health Justice, Community Giving and Employee Match Program
SOURCE: Gilead Sciences 
Via 3BL Media
Exposures COVID-19
Kite and Appia Bio Announce Collaboration to Research and Develop Allogeneic Cell Therapies for Cancer
From Kite, a Gilead Company
Via Business Wire
< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.